Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-10T07:11:44.015Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19)

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  19 April 2021

Valeria Fabre Open the ORCID record for Valeria Fabre [Opens in a new window] ,
Sara Karaba ,
Joe Amoah ,
Matthew Robinson ,
George Jones ,
Kathryn Dzintars ,
Morgan Katz ,
B. Mark Landrum ,
Sarojini Qasba  and
Pooja Gupta
...Show all authors
Valeria Fabre*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Antimicrobial Stewardship, The Johns Hopkins Hospital, Baltimore, Maryland
Sara Karaba
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Joe Amoah
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
Matthew Robinson
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
George Jones
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Kathryn Dzintars
Affiliation:
Department of Antimicrobial Stewardship, The Johns Hopkins Hospital, Baltimore, Maryland
Morgan Katz
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
B. Mark Landrum
Affiliation:
Howard County General Hospital, Columbia, Maryland
Sarojini Qasba
Affiliation:
Suburban Hospital, Bethesda, Maryland
Pooja Gupta
Affiliation:
Sibley Memorial Hospital, Washington, DC
Eili Klein
Affiliation:
Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland Center for Disease Dynamics, Economics & Policy, Washington, DC
Sara E. Cosgrove
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Antimicrobial Stewardship, The Johns Hopkins Hospital, Baltimore, Maryland
*
Author for correspondence: Valeria Fabre, MD, E-mail: mfabre1@jhmi.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To evaluate the role of procalcitonin (PCT) results in antibiotic decisions for COVID-19 patients at hospital presentation.

Design, setting, and participants:

Multicenter retrospective observational study of patients ≥18 years hospitalized due to COVID-19 at the Johns Hopkins Health system. Patients who were transferred from another facility with >24 hours stay and patients who died within 48 hours of hospitalization were excluded.

Methods:

Elevated PCT values were determined based on each hospital’s definition. Antibiotic therapy and PCT results were evaluated for patients with no evidence of bacterial community-acquired pneumonia (bCAP) and patients with confirmed, probable, or possible bCAP. The added value of PCT testing to clinical criteria in detecting bCAP was evaluated using receiving operating curve characteristics (ROC).

Results:

Of 962 patients, 611 (64%) received a PCT test. ROC curves for clinical criteria and clinical criteria plus PCT test were similar (at 0.5 ng/mL and 0.25 ng/mL). By bCAP group, median initial PCT values were 0.58 ng/mL (interquartile range [IQR], 0.24–1.14), 0.23 ng/mL (IQR, 0.1–0.63), and 0.15 ng/mL (IQR, 0.09–0.35) for proven/probable, possible, and no bCAP groups, respectively. Among patients without bCAP, an elevated PCT level was associated with 1.8 additional days of CAP therapy (95% CI, 1.01–2.75; P < .01) compared to patients with a negative PCT result after adjusting for potential confounders. Duration of CAP therapy was similar between patients without a PCT test ordered and a low PCT level for no bCAP and possible bCAP groups.

Conclusions:

PCT results may be abnormal in COVID-19 patients without bCAP and may result in receipt of unnecessary antibiotics.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 5 , May 2022 , pp. 570 - 575
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Melendi, GA, Laham, FR, Monsalvo, AC, et al. Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants. Pediatrics 2007;120:e410–e415.CrossRefGoogle ScholarPubMed
Gilbert, DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011;52 suppl 4:S346–S350.CrossRefGoogle Scholar
Schuetz, P, Christ-Crain, M, Muller, B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578–585.CrossRefGoogle ScholarPubMed
Townsend, J, Adams, V, Galiatsatos, P, et al. Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a United States medical center: results of a clinical trial. Open Forum Infect Dis 2018;5:ofy327.CrossRefGoogle Scholar
Huang, DT, Yealy, DM, Angus, DC, the Pro ACTI. Procalcitonin-guided antibiotic use. N Engl J Med 2018;379:1973.CrossRefGoogle Scholar
Cole, JL. Experience during the first year of procalcitonin implementation: a precautionary tale for smaller facilities. Infect Control Hosp Epidemiol 2018;39:1142–1143.CrossRefGoogle ScholarPubMed
Giamarellos-Bourboulis, EJ, Netea, MG, Rovina, N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020;27:992–1000.CrossRefGoogle ScholarPubMed
Ye, Q, Wang, B, Mao, J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect 2020;80:607–613.CrossRefGoogle ScholarPubMed
Pirofski, LA, Casadevall, A. Pathogenesis of COVID-19 from the perspective of the damage-response framework. mBio 2020;11. doi: 10.1128/mBio.01175-20.CrossRefGoogle ScholarPubMed
Vaughn, VM, Gandhi, T, Petty, LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with COVID-19: a multihospital cohort study. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1239.Google Scholar
Karaba, SM, Jones, G, Helsel, T, et al. Prevalence of coinfection at the time of hospital admission in COVID-19 patients, a multicenter study. Open Forum Infect Dis 2020. doi: 10.1093/ofid/ofaa578.Google Scholar
Amoah, J, Stuart, EA, Cosgrove, SE, et al. Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections. Clin Infect Dis 2020;71:e497–e505.Google ScholarPubMed
Garibaldi, BT, Fiksel, J, Muschelli, J, et al. Patient trajectories among persons hospitalized for COVID-19: a cohort study. Ann Intern Med 2021;174:33–41.CrossRefGoogle ScholarPubMed
Zhang, JJ, Dong, X, Cao, YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730–1741.CrossRefGoogle ScholarPubMed
Lippi, G, Plebani, M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020;58:1131–1134.CrossRefGoogle ScholarPubMed
Kamat, IS, Ramachandran, V, Eswaran, H, Guffey, D, Musher, DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2019;70:538–542.CrossRefGoogle Scholar
Supplementary material: File

Fabre et al. supplementary material

Fabre et al. supplementary material

Download Fabre et al. supplementary material(File)
File 59.2 KB